- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- May 2025
- 192 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 197 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 191 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 197 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 196 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 488 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- April 2025
- 200 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Drug Pipelines
- April 2025
- 150 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Report
- July 2024
- 231 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- February 2025
- 182 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- October 2023
- 85 Pages
United States
From €4344EUR$4,850USD£3,703GBP
- Report
- October 2022
- 270 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- May 2022
- 196 Pages
Global
From €2351EUR$2,625USD£2,004GBP
€4702EUR$5,250USD£4,009GBP
- Report
- January 2024
- 244 Pages
Global
From €4478EUR$5,000USD£3,818GBP
- Report
- May 2024
- 136 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- October 2021
- 104 Pages
Global
From €4031EUR$4,500USD£3,436GBP
Tofacitinib is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking the action of certain enzymes that are involved in the body's inflammatory response. Tofacitinib is taken orally, usually twice daily. It is available in both tablet and solution form.
Tofacitinib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the first JAK inhibitor to be approved for the treatment of immune disorders. Since its approval, it has become a popular treatment option for many patients.
The market for Tofacitinib is highly competitive, with several companies offering the drug. These include Pfizer, Novartis, AbbVie, and Merck. Each company has its own formulation of the drug, and they compete on price, efficacy, and safety. Show Less Read more
